The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Fixed-duration epcoritamab + R-CHOP in newly diagnosed higher-risk DLBCL: follow-up of EPCORE NHL-2
Lorenzo Falchi, MD, Memorial Sloan Kettering Cancer Center, New York, NY, outlines the findings from the 38.8-month follow-up of the EPCORE NHL-2 trial (NCT04663347), specifically of the arm comparing fixed-duration epcoritamab plus R-CHOP to R-CHOP alone in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) and high International Prognostic Index (IPI) scores. Dr Falchi highlights that the results have been encouraging, with many patients achieving deep and durable responses. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
